RAGE Biotech is developing splice-switching oligonucleotide (SSO) therapeutics that inhibit the Receptor for Advanced Glycation End-products (RAGE) to target chronic inflammatory diseases such as COPD and severe asthma. By utilizing RNA-targeting technologies, the company aims to provide effective treatments for patients suffering from difficult-to-treat inflammatory conditions.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IGFounders
Product
Problem
Chronic inflammatory diseases like COPD and severe asthma are difficult to treat effectively due to the complex nature of inflammation and the multitude of potential triggers. Traditional drug development approaches often struggle to address the underlying mechanisms driving these conditions. There is a need for more targeted therapies that can effectively modulate the inflammatory response and improve patient outcomes.
Solution
RAGE Biotech is developing novel therapeutics that target the Receptor for Advanced Glycation End-products (RAGE), a key mediator of inflammation in a wide range of chronic diseases. The company utilizes RNA-targeting technologies, specifically splice-switching oligonucleotides (SSOs), to inhibit RAGE activation and modulate the inflammatory cascade. By selectively modifying RNA splicing, RAGE Biotech's approach aims to provide a more precise and effective way to control inflammation compared to traditional methods. Their lead drug candidate is being developed as an inhaled treatment for chronic lung diseases, offering the potential for localized delivery and reduced systemic side effects. The company's technology aims to address the root causes of chronic inflammation, offering hope for patients with difficult-to-treat conditions.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory diseases such as COPD, severe asthma, and cystic fibrosis, as well as the physicians and healthcare providers who treat these conditions.
Features
- Splice-switching oligonucleotide (SSO) technology to selectively modulate RNA splicing of the RAGE receptor
- RNA-targeted therapeutics designed to inhibit RAGE activation and reduce inflammation
- Inhaled drug delivery for localized treatment of chronic lung diseases such as COPD and severe asthma
- Therapeutic peptide technologies to inhibit RAGE
- Programs targeting COPD, chronic kidney disease and other inflammatory diseases